scholarly journals Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model

2014 ◽  
Vol 29 (9) ◽  
pp. 1125-1133 ◽  
Author(s):  
Souha Mahmoudi ◽  
Daniel Lévesque ◽  
Pierre J. Blanchet
Keyword(s):  
Tardive Dyskinesia ◽  
D2 Receptors ◽  
Primate Model ◽  
Dopamine D3

scholarly journals Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans

2015 ◽  
Vol 41 (2) ◽  
pp. 529-537 ◽  
Author(s):  
Bernard Le Foll ◽  
Doris Payer ◽  
Patricia Di Ciano ◽  
Mihail Guranda ◽  
Shinichiro Nakajima ◽  
...  
Keyword(s):  
D2 Receptors ◽  
Dopamine D3

scholarly journals Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics

2002 ◽  
Vol 56 (4) ◽  
pp. 469-474 ◽  
Author(s):  
SUNG-IL WOO ◽  
JAE WON KIM ◽  
EUGENE RHA ◽  
SUN-HO HAN ◽  
KYU-HEE HAHN ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Receptor Gene ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Dopamine D3

Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors

2009 ◽  
Vol 19 (8) ◽  
pp. 2133-2138 ◽  
Author(s):  
Jean-Louis Peglion ◽  
Christophe Poitevin ◽  
Clotilde Mannoury La Cour ◽  
Delphine Dupuis ◽  
Mark J. Millan
Keyword(s):  
D2 Receptors ◽  
Dopamine D3

Dopamine D3 receptor variant and tardive dyskinesia

2000 ◽  
Vol 250 (1) ◽  
pp. 31-35 ◽  
Author(s):  
M. Rietschel ◽  
H. Krauss ◽  
D. J. Müller ◽  
T. G. Schulze ◽  
M. Knapp ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Dopamine D3

scholarly journals Dopamine D3 Receptor Ligand Suppresses the Expression of Levodopa-Induced Dyskinesia in Nonhuman Primate Model of Parkinson's Disease

2021 ◽  
Author(s):  
Thomas Oh ◽  
Elyas Daadi ◽  
Jeffrey Kim ◽  
Etienne Daadi ◽  
Peng-Jen Chen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Partial Agonist ◽  
Nigrostriatal System ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Lead Compound ◽  
Primate Model ◽  
Medical Needs ◽  
Dopamine D3

Abstract Parkinson’s disease (PD) is a complex multisystem, chronic and so far incurable disease with significant unmet medical needs. The incidence of PD increases with aging and the expected burden will continue to escalate with our aging population. Since its discovery in the 1961 levodopa remains the gold standard pharmacotherapy for PD. However, the progressive nature of the neurodegenerative process in and beyond the nigrostriatal system causes a multitude of side effects, including levodopa-induced dyskinesia within 5 years of therapy. Attenuating dyskinesia has been a significant challenge in the clinical management of PD. We report on a small molecule that eliminates the expression of levodopa-induced dyskinesia and significantly improves PD-like symptoms. The lead compound PD13R we discovered is a dopamine D3 receptor partial agonist with high affinity and selectivity, orally active and with desirable drug-like properties. Future studies are aimed at developing this lead compound for treating PD patients with dyskinesia.

scholarly journals Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients

2000 ◽  
Vol 3 (1) ◽  
pp. 61-65 ◽  
Author(s):  
Roger Løvlie ◽  
Ann K. Daly ◽  
Richard Blennerhassett ◽  
Nicol Ferrier ◽  
Vidar M. Steen
Keyword(s):  
Tardive Dyskinesia ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Schizophrenic Patients ◽  
Dopamine D3
Sign in / Sign up

Export Citation Format

Share Document